BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jodele S. Complement in Pathophysiology and Treatment of Transplant-Associated Thrombotic Microangiopathies. Semin Hematol 2018;55:159-66. [PMID: 30032753 DOI: 10.1053/j.seminhematol.2018.04.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel) 2022;15:845. [PMID: 35890144 DOI: 10.3390/ph15070845] [Reference Citation Analysis]
2 Madsen K, Pelletier K, Côté G, Kitchlu A, Chen S, Mattsson J, Pasic I. Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. Bone Marrow Transplant 2022. [PMID: 35752740 DOI: 10.1038/s41409-022-01744-0] [Reference Citation Analysis]
3 Jodele S, Dandoy CE, Sabulski A, Koo J, Lane A, Myers KC, Wallace G, Chima RS, Teusink-cross A, Hirsch R, Ryan TD, Benoit S, Davies SM. TA-TMA risk stratification: is there a window of opportunity to improve outcomes? Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.04.019] [Reference Citation Analysis]
4 Qi J, Hu S, He X, Pan T, Yang L, Zhang R, Tang Y, Wu D, Han Y. N-Acetyl-L-Cysteine Potentially Inhibits Complement Activation in Transplantation-Associated Thrombotic Microangiopathy. Transplant Cell Ther 2021:S2666-6367(21)01451-2. [PMID: 34979328 DOI: 10.1016/j.jtct.2021.12.018] [Reference Citation Analysis]
5 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
6 Kaya AH, Tekgunduz E. Management of thrombotic microangiopathy after hematopoietic cell transplantation: A position statement of ThREG (Turkish Hematology Research and Education Group). Transfus Apher Sci 2021;:103313. [PMID: 34785151 DOI: 10.1016/j.transci.2021.103313] [Reference Citation Analysis]
7 Sharif MO, Leavis HL, van Paassen P, van Rhenen A, Timmermans SAMEG, Ton E, Laar JMV, Spierings J. Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report. Rheumatology (Oxford) 2021;60:e326-8. [PMID: 33711097 DOI: 10.1093/rheumatology/keab239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tamburro RF, Cooke KR, Davies SM, Goldfarb S, Hagood JS, Srinivasan A, Steiner ME, Stokes D, DiFronzo N, El-Kassar N, Shelburne N, Natarajan A; Pulmonary Complications of Pediatric Hematopoietic Stem Cell Transplantation Workshop Participants. Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. Ann Am Thorac Soc 2021;18:381-94. [PMID: 33058742 DOI: 10.1513/AnnalsATS.202001-006OT] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yang LP, Liu X, Zhang XH. [Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2021;42:693-9. [PMID: 34547882 DOI: 10.3760/cma.j.issn.0253-2727.2021.08.018] [Reference Citation Analysis]
10 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Reference Citation Analysis]
11 Luft T, Dreger P, Radujkovic A. Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation. Bone Marrow Transplant 2021. [PMID: 34253879 DOI: 10.1038/s41409-021-01390-y] [Reference Citation Analysis]
12 Zhang R, Qi J, Zhou M, Pan T, Zhang Z, Yao Y, Han H, Han Y. Upregulation of Nrf2 Attenuates Oxidative Stress-Induced, Complement Activation-Associated Endothelial Injury and Apoptosis in Transplant-Associated Thrombotic Microangiopathy. Transplant Cell Ther 2021;27:758.e1-8. [PMID: 34174470 DOI: 10.1016/j.jtct.2021.06.017] [Reference Citation Analysis]
13 Sabulski A, Szabo S, Myers KC, Davies SM, Jodele S. Testicular thrombotic microangiopathy: An unrecognized complication. Pediatr Blood Cancer 2021;68:e29128. [PMID: 34019336 DOI: 10.1002/pbc.29128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, Kanda J, Ishikawa T, Imada K, Ueda Y, Toda Y, Anzai N, Yago K, Nohgawa M, Yonezawa A, Tsunemine H, Itoh M, Yamamoto K, Tsuji M, Moriguchi T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv 2020;4:3169-79. [PMID: 32658984 DOI: 10.1182/bloodadvances.2020002007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
15 Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 2020;4:1166-77. [PMID: 32208488 DOI: 10.1182/bloodadvances.2020001515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
16 Elfeky R, Lucchini G, Lum SH, Ottaviano G, Builes N, Nademi Z, Battersby A, Flood T, Owens S, Cant AJ, Young H, Greener S, Walsh P, Kavanagh D, Annavarapu S, Rao K, Amrolia P, Chiesa R, Worth A, Booth C, Skinner R, Doncheva B, Standing J, Gennery AR, Qasim W, Slatter M, Veys P. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv 2020;4:2418-29. [PMID: 32492158 DOI: 10.1182/bloodadvances.2019001315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Schoettler M, Lehmann LE, Margossian S, Lee M, Kean LS, Kao PC, Ma C, Duncan CN. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv 2020;4:2536-47. [PMID: 32516415 DOI: 10.1182/bloodadvances.2019001242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021;56:1805-17. [PMID: 33875812 DOI: 10.1038/s41409-021-01283-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol 2021;14:101081. [PMID: 33862523 DOI: 10.1016/j.tranon.2021.101081] [Reference Citation Analysis]
20 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol 2021;8:e229-39. [PMID: 33636143 DOI: 10.1016/S2352-3026(20)30404-X] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, Han Y. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:564647. [PMID: 33552043 DOI: 10.3389/fimmu.2020.564647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
24 Mariotti J, Penack O, Castagna L. Acute Graft-versus-Host-Disease Other Than Typical Targets: Between Myths and Facts.Transplant Cell Ther. 2021;27:115-124. [PMID: 33017661 DOI: 10.1016/j.bbmt.2020.09.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2306-10. [PMID: 32961372 DOI: 10.1016/j.bbmt.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Gloude NJ, Dandoy CE, Davies SM, Myers KC, Jordan MB, Marsh RA, Kumar A, Bleesing J, Teusink-Cross A, Jodele S. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. J Clin Immunol 2020;40:699-707. [PMID: 32447592 DOI: 10.1007/s10875-020-00789-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
27 Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfus Med Rev 2019;33:256-65. [PMID: 31703946 DOI: 10.1016/j.tmrv.2019.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
28 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019;18:707-29. [PMID: 31324874 DOI: 10.1038/s41573-019-0031-6] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 33.0] [Reference Citation Analysis]
29 Bhunia N, Abu-Arja R, Bajwa RPS, Auletta JJ, Rangarajan HG. Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease. Pediatr Blood Cancer 2019;66:e27912. [PMID: 31264793 DOI: 10.1002/pbc.27912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Dvorak CC, Higham C, Shimano KA. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Front Pediatr 2019;7:133. [PMID: 31024873 DOI: 10.3389/fped.2019.00133] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
31 Jia C, Qin M, Wang B, Zhu G, Yan Y. Variable clinical manifestations of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Pediatr Investig 2018;2:253-6. [PMID: 32851275 DOI: 10.1002/ped4.12100] [Reference Citation Analysis]
32 Risitano AM. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Semin Hematol 2018;55:113-7. [PMID: 30032746 DOI: 10.1053/j.seminhematol.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]